Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia - PubMed (original) (raw)
Comparative Study
. 2004 Jan 1;124B(1):1-5.
doi: 10.1002/ajmg.b.20045.
Affiliations
- PMID: 14681904
- DOI: 10.1002/ajmg.b.20045
Comparative Study
Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia
György Szekeres et al. Am J Med Genet B Neuropsychiatr Genet. 2004.
Abstract
Molecular components of the dopaminergic system may play an important role in the pathophysiology of schizophrenia. In this study, we investigated the relationship of the Ser9Gly (S/G) polymorphism of the dopamine D3 receptor (DRD3) and the variable number of tandem repeats (VNTR) polymorphism of the dopamine transporter (DAT) with therapeutic response to atypical antipsychotics (clozapine, olanzapine, quetiapine, risperidone) and cognitive functions. No associations were found between the DRD3 and DAT polymorphisms and schizophrenia. The S/S genotype and the S allele were more frequent in the non-responder patients (n = 28) than in the group of responders (n = 47) (cut-off: >20-point improvement in Global Assessment of Functioning (GAF) scale). The patients with S/S genotype completed fewer categories and had more perseverative errors in the Wisconsin Card Sorting Test (WCST) compared with the S/G patients. The S/S and S/G patients did not differ in positive and negative symptoms, GAF scores, WCST failure to maintain set, and verbal learning. No differences in symptoms or WCST measures were observed in the patients with different DAT genotypes. These results suggest that the S/S genotype of the DRD3 is associated with worse therapeutic response and more severe executive dysfunctions in patients with schizophrenia.
Copyright 2003 Wiley-Liss, Inc.
Similar articles
- The dopamine D3 receptor (DRD3) Ser9Gly polymorphism and schizophrenia: a haplotype relative risk study and association with clozapine response.
Malhotra AK, Goldman D, Buchanan RW, Rooney W, Clifton A, Kosmidis MH, Breier A, Pickar D. Malhotra AK, et al. Mol Psychiatry. 1998 Jan;3(1):72-5. doi: 10.1038/sj.mp.4000288. Mol Psychiatry. 1998. PMID: 9491816 - Dopamine D3 receptor Ser9Gly polymorphism and risperidone response.
Lane HY, Hsu SK, Liu YC, Chang YC, Huang CH, Chang WH. Lane HY, et al. J Clin Psychopharmacol. 2005 Feb;25(1):6-11. doi: 10.1097/01.jcp.0000150226.84371.76. J Clin Psychopharmacol. 2005. PMID: 15643094 Clinical Trial. - Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics.
Tauscher J, Hussain T, Agid O, Verhoeff NP, Wilson AA, Houle S, Remington G, Zipursky RB, Kapur S. Tauscher J, et al. Am J Psychiatry. 2004 Sep;161(9):1620-5. doi: 10.1176/appi.ajp.161.9.1620. Am J Psychiatry. 2004. PMID: 15337652 - Quetiapine versus other atypical antipsychotics for schizophrenia.
Asmal L, Flegar SJ, Wang J, Rummel-Kluge C, Komossa K, Leucht S. Asmal L, et al. Cochrane Database Syst Rev. 2013 Nov 18;(11):CD006625. doi: 10.1002/14651858.CD006625.pub3. Cochrane Database Syst Rev. 2013. PMID: 24249315 Review. - New antipsychotics and schizophrenia: a review on efficacy and side effects.
Serretti A, De Ronchi D, Lorenzi C, Berardi D. Serretti A, et al. Curr Med Chem. 2004 Feb;11(3):343-58. doi: 10.2174/0929867043456043. Curr Med Chem. 2004. PMID: 14965236 Review.
Cited by
- Investigation of possible association between Ser9Gly polymorphism of the D3 dopaminergic receptor gene and response to typical antipsychotics in patients with schizophrenia.
Cordeiro Q, Miguita K, Miracca E, Elkis H, Vallada H. Cordeiro Q, et al. Sao Paulo Med J. 2006 May 4;124(3):165-7. doi: 10.1590/s1516-31802006000300013. Sao Paulo Med J. 2006. PMID: 17119697 Free PMC article. - A dopaminergic mechanism of antipsychotic drug efficacy, failure, and failure reversal: the role of the dopamine transporter.
Amato D, Canneva F, Cumming P, Maschauer S, Groos D, Dahlmanns JK, Grömer TW, Chiofalo L, Dahlmanns M, Zheng F, Kornhuber J, Prante O, Alzheimer C, von Hörsten S, Müller CP. Amato D, et al. Mol Psychiatry. 2020 Sep;25(9):2101-2118. doi: 10.1038/s41380-018-0114-5. Epub 2018 Jul 23. Mol Psychiatry. 2020. PMID: 30038229 Free PMC article. - Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis.
Need AC, Keefe RS, Ge D, Grossman I, Dickson S, McEvoy JP, Goldstein DB. Need AC, et al. Eur J Hum Genet. 2009 Jul;17(7):946-57. doi: 10.1038/ejhg.2008.264. Epub 2009 Jan 21. Eur J Hum Genet. 2009. PMID: 19156168 Free PMC article. - The potential role of dopamine D₃ receptor neurotransmission in cognition.
Nakajima S, Gerretsen P, Takeuchi H, Caravaggio F, Chow T, Le Foll B, Mulsant B, Pollock B, Graff-Guerrero A. Nakajima S, et al. Eur Neuropsychopharmacol. 2013 Aug;23(8):799-813. doi: 10.1016/j.euroneuro.2013.05.006. Epub 2013 Jun 20. Eur Neuropsychopharmacol. 2013. PMID: 23791072 Free PMC article. Review. - Factors associated with response to clozapine in schizophrenia: a review.
Suzuki T, Uchida H, Watanabe K, Kashima H. Suzuki T, et al. Psychopharmacol Bull. 2011;44(1):32-60. Psychopharmacol Bull. 2011. PMID: 22506438 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases